Barabio

Name

Barabio

Legal name

HLB Lifecare co., Ltd.

Website

https://barabio.co.kr

Company type

Private

Founded year

2021

Operating status

Operating

Ownership category

akta.pro rank

Product category

Digital Healthcare - Senior Chronic Disease Management

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834)

akta.pro primary industry

Continuous Glucose Monitoring (CGM) Systems (HLAHAHAA)

akta.pro secondary industry

Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ)

Keywords

• Digital healthcare
• Chronic disease management
• Continuous glucose monitoring
• AI disease prediction
• Immuno-oncology drugs

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Distribution channels1 record

Marketing channels3 records

Core offering

Barabio (HLB Lifecare) develops and delivers an AI-based chronic disease prediction and management platform targeting senior patients with diabetes and related metabolic conditions, combined with an MFDS-approved personal continuous blood glucose monitor (CGM) wearable device and personalized functional foods for chronic disease prevention. The company also pursues next-generation immuno-oncology drug development, including CD96-targeting antibodies and ADCs for triple-negative breast cancer, through partnerships with hospitals, universities, and HLB Group biotech subsidiaries.

Product overview

Barabio (HLB Lifecare) operates as a digital healthcare and biopharma company focused on senior chronic disease management. Its portfolio spans a unified platform architecture combining: (1) an AI-based chronic disease prediction and management platform — the core digital health offering that provides ultra-personalized diabetes and chronic disease care; (2) a personal continuous blood glucose monitor — an MFDS-approved wearable medical device enabling real-time glucose tracking; (3) functional food/ingredient products — personalized dietary solutions tied to disease management; (4) Picoling — a named digital healthcare sub-brand; and (5) a next-generation immunotherapy/biopharma program targeting cancer through CD96 antibody and ADC drug development. The digital healthcare products and the biopharma division operate as distinct but complementary pillars under the Barabio/HLB Lifecare umbrella.

Differentiator

Problem solved

Functional benefit

Products and services

• AI-Based Chronic Disease Prediction Management Platform (AI기반 예측관리)

Segments1 record

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Partnerships

14 partnerships are on record, tiered core and minor.

• 바디텍메드 (BodyTekMed)coreStrategic or Co-development Partner · 12 March 2026Collaboration on diagnostic support solution development using AI to predict diabetes and chronic diseases.
• 서울송도병원 (Seoul Songdo Hospital)coreStrategic or Co-development Partner · 12 March 2026Digital healthcare forum and telemedicine cooperation for seniors. Development of 4th generation cancer drugs including CD96-based antibody for triple-negative breast cancer.
• 한국영양의학회 (Korean Society for Nutrition)minorStrategic or Co-development Partner · 12 March 2026MOU for 'disease prevention through personalized diet research' focusing on metabolic disease management.
• 아이센스 (i-Sens)coreTechnology or Integration · 12 March 2026AI-based chronic disease management business model development partnership.
• 네메시스 (Nemesis)minorStrategic or Co-development Partner · 12 March 2026Biosignal processing joint development MOU for chronic metabolic disease digital healthcare research.
• 휴레이포지티브 (Hurray Positive)minorStrategic or Co-development Partner · 12 March 2026Digital healthcare business promotion MOU to improve medical environment and regional healthcare services for cancer and chronic metabolic diseases.
• 에이비켐바이오 (AB KemBio)coreStrategic or Co-development Partner · 12 March 2026Immuno-cancer drug development MOU focusing on ADC drugs and triple-negative breast cancer treatment.
• 강남세브란스 (Kangnam Severance Hospital)coreStrategic or Co-development Partner · 12 March 2026Partnership in cancer research forum focused on triple-negative breast cancer treatment through immune checkpoint inhibitors and ADC development.
• 서울시니어스타워 (Seoul Senior Tower)minorStrategic or Co-development Partner · 12 March 2026MOU to build a 'smart city' for retirees through mutual cooperation.
• 양양군 (Yangyang County)minorStrategic or Co-development Partner · 12 March 2026Telemedicine cooperation agreement with Seoul Songdo Hospital and Yangyang County for remote healthcare services.
• 라이온스 서울지구 (Lions Club Seoul District)minorGTM or Marketing Partner · 12 March 2026CEO Ahn Cheol-woo appointed as Diabetes Prevention Research Center Director for senior diabetes prevention initiatives.
• 대한노인회 (Korean Senior Association)minorGTM or Marketing Partner · 12 March 2026CEO Ahn Cheol-woo appointed as 'Diabetes Primary Care Physician' for senior health management programs.
• HLB 제 약/바이오 그룹사 (HLB Pharma/Bio Group Companies)coreStrategic or Co-development Partner · 12 March 2026Synergy with HLB group's pharmaceutical and biotech companies including HLB Panagen, HLB Biostack, HLB生命科学, HLB Biocode, HLB Therapeu tics, HLB Pharma, HLB Genex, and HLB Global for integrated healthcare solutions.
• 연세대학교 (Yonsei University)coreStrategic or Co-development Partner · 1 January 2024AI-based digital healthcare MOU for research collaboration in chronic disease management and predictive analytics.

Recent moves6 records

Expansion highlights6 records

Regional players

• Celltrion: Celltrion is a major Korean biopharmaceuticals and biosimilars company; comparable as a regional Korean player with overlapping oncology/biologics ambitions relevant to Barabio's CD96 and ADC programs.
• Daewoong Pharmaceutical: Daewoong is a Korean pharmaceutical and biotech company with adjacent metabolic and chronic disease programs; relevant as a regional comparable in the same Korean healthcare ecosystem where Barabio is positioned.

Broad incumbents

• Medtronic Diabetes: Medtronic operates a diabetes business spanning CGM, insulin pumps, and automated insulin delivery systems; it competes broadly with Barabio's device plus AI-platform approach to diabetes management.
• Roche Diabetes Care: Roche operates a major diabetes care franchise (Accu-Chek, digital diabetes management) that competes across both glucose monitoring and digital chronic disease management where Barabio operates.
• Abbott Diabetes Care: Abbott's FreeStyle Libre line is the dominant consumer CGM globally; as a broad incumbent in diabetes care, Abbott competes directly with Barabio's personal CGM and AI-driven diabetes management offering.

Direct peers

• Dexcom: Dexcom is the global leader in continuous glucose monitoring systems (G5/G6/G7); Barabio's MFDS-approved personal CGM directly competes with Dexcom's platform for diabetes and chronic disease management.
• i-Sens: i-Sens is a Korean diagnostics company with blood-glucose monitoring products including CGM systems and is also a named Barabio partnership partner, making it a directly comparable Korean competitor.

Emerging players

• DarioHealth: DarioHealth combines a smart glucometer with an AI-driven chronic disease management platform, closely mirroring Barabio's device-plus-software positioning for diabetes and metabolic care.
• Ypsomed: Ypsomed produces CGM systems (via YpsoPump and partner-integrated solutions) and self-care devices; it is a focused European CGM-adjacent peer with comparable device-plus-platform ambitions.
• Omada Health: Omada is a digital chronic care company (diabetes, hypertension, prediabetes) using AI-powered personalization; Barabio's chronic disease prediction platform overlaps on the digital therapeutics and senior care layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barabio